Literature DB >> 2872036

Identification of the main urinary metabolites of omeprazole after an oral dose to rats and dogs.

K J Hoffmann.   

Abstract

The structures of seven urinary metabolites of omeprazole following high oral doses to rats and dogs were determined unambiguously by combining different analytical and spectroscopic techniques including derivatization and stable isotopes. Omeprazole was metabolized by aromatic hydroxylation at position 6 in the benzimidazole ring followed by glucuronidation. There was also oxidative O-dealkylation of both methoxy groups, and aliphatic hydroxylation of a pyridine methyl group followed by oxidation to the corresponding carboxylic acid. Due to the experimental design, implying no pH control of collected samples, all metabolites were isolated as sulfides. They were formed in both species with quantitative variations in the metabolic pattern. As far as identified metabolites are concerned, aromatic hydroxylation and subsequent glucuronide formation were the major biotransformation routes in the dog. In the rat, aliphatic hydroxylation and the formation of the carboxylic acid represented the major metabolic pathways. The identified metabolites corresponded approximately to 50% (rat) and 70% (dog) of the amount excreted in the 0-24-hr urine (about 12% of the given dose in both species).

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2872036

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  3 in total

1.  Effect of omeprazole on diazepam disposition in the rat: in vitro and in vivo studies.

Authors:  K Zomorodi; J B Houston
Journal:  Pharm Res       Date:  1995-11       Impact factor: 4.200

2.  In vivo metabolism of the anti-inflammatory agent 2-(5-ethylpyridin-2-yl)benzimidazole.

Authors:  O Caputo; G Grosa; M Ceruti; F Viola; F Rocco
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1989 Oct-Dec       Impact factor: 2.441

Review 3.  Omeprazole. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in peptic ulcer disease and Zollinger-Ellison syndrome.

Authors:  S P Clissold; D M Campoli-Richards
Journal:  Drugs       Date:  1986-07       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.